• S&P 500: 1,342.64
  • Change: -0.69%
$13.32 -0.31 (-2.24%)
2/10/2012 4:00 PM

ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 3 out of 5

The Company develops antibody-based anticancer therapeutics.

Current Price $13.32 Mkt Cap $1.02B
Open $13.58 P/E Ratio 0.00
Prev. Close $13.63 Div. (Yield) N/A (N/A)
Daily Range $13.17 - $13.71 Volume 511,878
52-Wk Range $8.31 - $16.20 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think IMGN will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

276 Outperform
20 Underperform
 

All-Star Players

80 Outperform
3 Underperform
 

Wall Street

9 Outperform
1 Underperform
 

Top IMGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBreakerThiel (93.43)
Submitted September 28, 2010

Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has failed other treatments.

Add Comment | Reply | Report this Post

NetscribeHealthC (< 20)
Submitted February 14, 2007

ImmunoGen develops therapeutics for the treatment of cancer. The company’s tumor-activated prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to treat cancer cells. Its collaborative partners include Amgen,… More

Add Comment | Reply | Report this Post
IMGN VS S&P 500 (SPY)

Fools bullish on IMGN are also bullish on:

Fools bearish on IMGN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about IMGN.

Recs

0
Member Avatar kmv98finance (< 20) Submitted: 1/31/2012 12:56:29 PM : Outperform Start Price: $14.14 IMGN Score: -8.31

This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar quinpeung (96.62) Submitted: 12/20/2011 12:04:50 PM : Underperform Start Price: $11.72 IMGN Score: -4.80

Market overreacted to recent LLY deal.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar thomluc3 (< 20) Submitted: 10/1/2011 3:36:01 PM : Outperform Start Price: $10.83 IMGN Score: +3.60

Good approach to cancer therapy. A step away from traditional chemotherapy. Any breakthrough in adenocarcinoma tumor therapy will lead to application for prostate carcinoma. We have not had any real therapeutic breakthrough in a long time. The tools are now in the workshop!

Report this Post Add Comment | Reply | Permalink
View All 33 Pitches »

Leaderboard

Find the members with the highest scoring picks in IMGN.

Score Leader

laugef

laugef (85.38) Score: +356.01

The Score Leader is the player with the highest score across all their picks in IMGN.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
laugef 85.38 10/10/2008 Outperform 5Y $2.57 +418.48% +62.48% +356.01 0 Comment
jmalott86 28.02 3/12/2008 Outperform 3Y $2.99 +345.65% +4.91% +340.74 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 69.43 7/7/2008 Outperform NS $3.30 +303.79% +9.32% +294.47 0 Comment
keljor < 20 4/28/2008 Outperform NS $3.44 +287.35% -0.34% +287.70 1 Comment
jrourke96 < 20 8/28/2006 8/1/2009 Outperform 3M $3.36 +296.58% +10.46% +286.11 0 Comment
nakovikes 91.80 3/13/2008 Outperform NS $3.44 +287.35% +8.04% +279.31 0 Comment
clucus < 20 9/21/2006 Outperform 1Y $3.54 +276.41% +7.54% +268.87 0 Comment
slowmoneys 84.35 1/18/2008 Outperform NS $3.60 +270.14% +4.02% +266.12 0 Comment
pdgecko 87.17 1/4/2008 Outperform 3Y $3.81 +249.74% -2.31% +252.05 0 Comment
tcramer649 82.50 10/26/2006 11/23/2009 Outperform 5Y $3.86 +245.21% +2.82% +242.39 2 Comments
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackZacks 71.09 9/23/2010 Underperform 3M $5.52 +141.39% +19.43% -121.96 1 Comment
TrackCanaccord 88.91 3/4/2010 Outperform NS $7.10 +87.68% +19.49% +68.19 0 Comment
TrackJimCramer 78.17 11/4/2009 Outperform 3W $6.72 +98.29% +28.06% +70.23 0 Comment
TrackBreanMurray 65.65 10/8/2009 Outperform NS $7.98 +66.98% +26.10% +40.88 0 Comment
TrackOppenheimer 79.13 7/7/2009 Outperform NS $8.77 +51.94% +50.49% +1.45 0 Comment
TrackMorganJos 56.19 8/4/2008 Outperform NS $4.98 +167.57% +9.96% +157.61 0 Comment
TrackRBCCapMkts 93.36 10/15/2007 Outperform NS $4.80 +177.60% -9.92% +187.52 0 Comment
TrackFerrisBaker 88.58 10/4/2007 Outperform NS $4.52 +194.80% -8.49% +203.29 0 Comment
TrackEveillard 96.04 9/30/2007 Outperform NS $4.65 +186.56% -7.74% +194.30 1 Comment
TrackLazardCapit 78.92 5/30/2007 Outperform NS $5.75 +46.96% -41.72% +88.67 7/13/2009 @ $8.45 0 Comment
TrackCantorFitz 52.55 11/22/2006 Outperform NS $4.56 +192.21% +1.25% +190.97 0 Comment

Featured Broker Partners